Complex Ther Med: S.officinalis extract prevents insulin resistance in patients with polycystic ovary syndrome.

The study, a randomized, triple-blind, controlled trial designed to assess the effects of S. officinalis extract on "anthrmosia index" and "insulin resistance markers" in patients with polycystic ovary syndrome (PCOS), was published online online.
included 60 PCOS patients diagnosed according to Rotterdam standards.
take 330mg oral S. officinalis extract or placebo capsule daily for 8 weeks.
body mass index (BMI), waist-to-hip ratio (WHR), blood pressure, steady-state model assessment -insulin resistance (HOMA-IR) and quantitative insulin sensitivity test index (QUICKI).
results show a significant decrease in BMI in the S. officinalis group (P s 0.001), but there is no significant difference in WWHR between the two groups (P s 0.164).
although it was not found that the S.officinalis extract had a significant effect on systolic pressure (P s 0.283), the multivariable model shows significant differences in espress pressure between the two groups (P s 0.025).
addition, taking S. officinalis extract significantly reduced levels of insulin (P .lt;0.001) and HOMA-IR (P.lt;0.001) compared to placebos.
, S.officinalis extract supplements led to a greater increase in QUICKI (P .lt; 0.001) than in the placebo group.
, the results showed that the dose of the S.officinalis extract was 330 mg/day, which reduced BMI and systolic blood pressure in patients with normal blood sugar PCOS, and enhanced insulin resistance markers.
.